当前位置: X-MOL 学术Blood Rev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Molecular targets in acute myelogenous leukemia.
Blood Reviews ( IF 7.4 ) Pub Date : 2002-12-20 , DOI: 10.1016/s0268-960x(02)00057-7
Derek L Stirewalt 1 , Soheil Meshinchi , Jerald P Radich
Affiliation  

Acute myeloid leukemia (AML) remains the most common form of leukemia and the most common cause of leukemia death. Although conventional chemotherapy can cure between 25 and 45% of AML patients, most patients will either die of relapse or die from the complications associated with treatment. Thus, more specific and less toxic treatments for AML patients are needed. Recently, a small molecular inhibitor (STI571 or Gleevec) that targets the BCR-ABL gene was found to have a dramatic clinical effect in patients with chronic myelogenous leukemia (CML). These results have encouraged investigators to search for additional small molecular inhibitors and other targeted therapies that may be applicable to other forms of leukemia. In this review, we examine some of the signaling pathways that are aberrantly regulated in AML, focusing on the tyrosine kinase/RAS/MAP kinase and JAK/STAT pathways. After reviewing these two pathways, we explore some of the targeted therapies directed at these pathways that are under development for AML, many of which are already in clinical trials.

中文翻译:

急性骨髓性白血病的分子靶标。

急性髓细胞性白血病(AML)仍然是白血病的最常见形式,也是白血病死亡的最常见原因。尽管常规化学疗法可以治愈25%至45%的AML患者,但大多数患者要么死于复发,要么死于与治疗相关的并发症。因此,需要针对AML患者的更特异性和毒性更低的治疗。最近,发现一种靶向BCR-ABL基因的小分子抑制剂(STI571或Gleevec)在慢性粒细胞性白血病(CML)患者中具有显着的临床效果。这些结果鼓励研究者寻找其他可能适用于其他形式白血病的小分子抑制剂和其他靶向疗法。在这篇评论中,我们研究了AML中异常调节的一些信号通路,重点研究酪氨酸激酶/ RAS / MAP激酶和JAK / STAT途径。在回顾了这两种途径之后,我们探索了针对这些正在针对AML开发的途径的靶向疗法,其中许多已经在临床试验中。
更新日期:2019-11-01
down
wechat
bug